Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of NBIX would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (1996) — listing | $513,977 11.3× | $747,010 11.4× |
| Year 6 (2001) | $390,678 10.2× | $568,497 10.2× |
| Year 11 (2006) | $362,018 11.8× | $526,747 11.8× |
| Year 16 (2011) | $134,727 5.8× | $196,208 5.8× |
| Year 21 (2016) | $28,763 1.8× | $41,794 1.8× |
| Year 26 (2021) | $11,427 1.4× | $16,631 1.4× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Headquarters
San Diego, California, United States
Popular scenarios with NBIX
For illustration only — not investment advice. Past performance is not indicative of future results.